Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Artículo Open Access |
| Published: |
Wiley
2024
|
| Subjects: | |
| Online Access: | https://onlinelibrary.wiley.com/doi/10.1111/ctr.70065 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Table of Contents:
- Evolving Impact of COVID‐19 on Intestinal Transplant Recipients: A Single‐Center Experience Colin Powers Brielle Corrente Jennifer Joyce William Stein Shelly Polydor Vikraman Gunabushanam Ajai Khanna Fernanda P. Silveira Ruy J. Cruz Clinical Transplantation ABSTRACTBackgroundThere has been significant concern about coronavirus disease 2019 (COVID‐19) among transplant recipients, particularly those who are highly immunosuppressed. Several studies have analyzed the impact of COVID‐19 on different solid organ transplant patients. However, few isolated case reports of COVID‐19 in intestinal and multivisceral transplant (ITx and MVTx) recipients are available in the literature. We report the first single‐center study evaluating the clinical course and outcome of COVID‐19 in ITx/MVTx recipients.MethodsAdult patients (age ≥ 18 years) with confirmed cases of COVID‐19 between February 2020 and February 2024 were included in this study.ResultsTwelve of the 67 (17.9%) ITx/MVTx recipients followed at our center had COVID‐19. Seven patients (58%) were female, and the median age at diagnosis was 47 years (range: 31–68 years). The average time from transplantation to COVID‐19 was 89 months (range: 14–215 months). Nine patients (75%) required hospitalization; three of them were admitted to the intensive care unit (ICU) and required ventilator support. One patient had COVID‐19 on two different occasions. Treatment modalities consisted of monoclonal antibody treatment (n = 5), of antiviral therapy (n = 4), and steroid monotherapy (n = 1). Three patients received combination therapy. Three patients (25%) developed irreversible respiratory failure and died after prolonged ventilator use.ConclusionsOur data suggested a possible increase in the incidence of COVID‐19 in ITx and MVTx recipients with an unchanged mortality rate despite the use of vaccines and new therapeutic modalities. Further multicenter studies are needed to analyze the real impact of COVID‐19 on this unique population. 10.1111/ctr.70065 http://creativecommons.org/licenses/by-nc-nd/4.0/